Clovis Oncology, Inc. CLVS was a big mover last session, as its shares rose over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the healthcare company since May 15, as the stock is now down over 31%.
In the last 30 days, the company has seen a mixed track record when it comes to estimate revisions of two increases and two decreases. However, the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked stocks in the medical sector include Gilead Sciences Inc. GILD, ANI Pharmaceuticals, Inc. ANIP and Illumina Inc. ILMN. All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CLOVIS ONCOLOGY CLVS: Free Stock Analysis Report
GILEAD SCIENCES GILD: Free Stock Analysis Report
ANI PHARMACEUT ANIP: Free Stock Analysis Report
ILLUMINA INC ILMN: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Market News and Data brought to you by Benzinga APIsIn the last 30 days, the company has seen a mixed track record when it comes to estimate revisions of two increases and two decreases. However, the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked stocks in the medical sector include Gilead Sciences Inc. GILD, ANI Pharmaceuticals, Inc. ANIP and Illumina Inc. ILMN. All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CLOVIS ONCOLOGY CLVS: Free Stock Analysis Report
GILEAD SCIENCES GILD: Free Stock Analysis Report
ANI PHARMACEUT ANIP: Free Stock Analysis Report
ILLUMINA INC ILMN: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
